NEW YORK (GenomeWeb News) – Response Genetics today announced it is joining Blue Shield of California's provider network, giving members of the health plan access to the Los Angeles-based molecular diagnostic firm's test portfolio.

The deal is Response Genetics' first contract with an affiliate of Blue Cross Blue Shield. Blue Shield of California has about 3 million members.

Among the products offered by Response Genetics are tests for colon, lung, gastric, and melanoma cancers, as well as tests for the detection of EGFR mutations, KRAS mutations, and others.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.